Research programme: CD30 antagonists - Boston Immune Technologies and Therapeutics
Alternative Names: Anti-CD30 antibody - Boston Immune Technologies and TherapeuticsLatest Information Update: 01 Apr 2021
At a glance
- Originator Boston Immune Technologies and Therapeutics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action CD30 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer